BioLife Sciences Inc.
BLFE
$0.00
$0.000.00%
| 02/28/2022 | |||||
|---|---|---|---|---|---|
| Revenue | -- | ||||
| Total Other Revenue | -- | ||||
| Total Revenue | -- | ||||
| Cost of Revenue | -- | ||||
| Gross Profit | -- | ||||
| SG&A Expenses | 110.63% | ||||
| Depreciation & Amortization | -- | ||||
| Other Operating Expenses | -- | ||||
| Total Operating Expenses | 110.63% | ||||
| Operating Income | -110.63% | ||||
| Income Before Tax | -95.85% | ||||
| Income Tax Expenses | -- | ||||
| Earnings from Continuing Operations | -95.85% | ||||
| Earnings from Discontinued Operations | -- | ||||
| Extraordinary Item & Accounting Change | -- | ||||
| Minority Interest in Earnings | -- | ||||
| Net Income | -95.85% | ||||
| EBIT | -110.63% | ||||
| EBITDA | -- | ||||
| EPS Basic | -91.67% | ||||
| Normalized Basic EPS | -75.00% | ||||
| EPS Diluted | -91.67% | ||||
| Normalized Diluted EPS | -75.00% | ||||
| Average Basic Shares Outstanding | 5.41% | ||||
| Average Diluted Shares Outstanding | 5.41% | ||||
| Dividend Per Share | -- | ||||
| Payout Ratio | -- | ||||
